Anti-IL-2 receptor antibody vs. polyclonal anti-lymphocyte antibody as induction therapy in pediatric transplantation
Sylvie Di Filippo,
Sylvie Di Filippo
Hôpital Cardiovasculaire Louis Pradel, BP Lyon Montchat, 69394, Lyon cedex 03, France
Search for more papers by this authorSylvie Di Filippo,
Sylvie Di Filippo
Hôpital Cardiovasculaire Louis Pradel, BP Lyon Montchat, 69394, Lyon cedex 03, France
Search for more papers by this authorSylvie Di Filippo MD, Hôpital Cardiovasculaire Louis Pradel, BP Lyon Montchat, 69394, Lyon cedex 03, France
Tel.: 33 4 72 357 389
Fax: 33 4 72 357 049
E-mail: [email protected]
From the Pediatric Symposium at the ATC, Boston, MA – May 15, 2004.
Abstract
Abstract: Current concerns in pediatric transplantation focus on chronic rejection which commonly leads to graft loss, and on long-term maintenance immunosuppression toxicity. Acute rejection has been associated with the subsequent development of chronic rejection. Therefore, induction therapy may provide potential benefits by preventing early acute rejection episodes and allowing delayed administration of calcineurin inhibitors or steroid avoidance. This review of the literature showed that induction therapy can reduce early and recurrent acute rejection episodes after pediatric solid organ transplantation. Whether this might result in better long-term graft survival has still to be confirmed. However, induction therapy has beneficial effects in high-risk recipients and allows steroid avoidance or calcineurin inhibitor minimization. Because they are very well tolerated, anti-IL-2 receptor antibodies are increasingly preferred to rabbit-antithymocyte globulin, but the former have not yet been proven to be more effective or to have less late toxicity than polyclonal agents. Benefits in early outcome and no increase in adverse events lead to recommend the use of IL-2 receptor antagonists as induction therapy after pediatric organ transplantation.
References
- 1 Tejani A, Ping-Leung H, Emmett L, Stablein DM. Reduction in acute rejections decreases chronic rejection graft failure in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Am J Transplant 2002: 2: 142–147.
- 2 Reddy SC, Laughlin K, Webber SA. Immunosuppression in pediatric heart transplantation: 2003 and beyond. Curr Treat Options Cardiovasc Med 2003: 5: 417–428.
- 3 Ettenger RB. Antibody therapy as an induction regimen in pediatric renal transplantation. Transplant Proc 1999: 31: 2677–2678.
- 4 Smith JM, Nemeth TL, McDonald RA. Current immunosuppressive agents: efficacy, side effects, and utilization. Pediatr Clin North Am 2003: 50: 1283–1300.
- 5 Boucek MM, Edwards LB, Keck BM, et al. The Registry of the International Society for Heart and Lung Transplantation: sixth official pediatric report 2003. J Heart Lung Transplant 2003: 22: 636–652.
- 6 Hurault de Ligny B, Lebranchu Y, on behalf of the French Thymoglobuline Pharmacovigilance Study Group. The use of thymoglobuline induction in renal transplantation: a pharmacovigilance study. Transplant Proc 2000: 32: 351–352.
- 7 Kovarik JM, Gridelli BG, Martin S, et al. Basiliximab in pediatric liver transplantation: a pharmacokinetic-derived dosing algorithm. Pediatr Transplant 2002: 6: 224–230.
- 8 Di Filippo S, Boissonnat P, Sassolas F, et al. Rabbit antithymocyte globulin as induction immunotherapy in pediatric heart transplantation. Transplantation 2003: 75: 354–358.
- 9 Lebeck LK, Chang L, Lopez-McCormack C, Chinnock R, Boucek M. Polyclonal antithymocyte serum: immune prophylaxis and rejection therapy in pediatric heart transplantation patients. J Heart Lung Transplant 1993: 12: S286–292.
- 10 Boucek RJ, Naftel D, Boucek MM, et al., and the Pediatric Heart Transplant Study Group Induction immunotherapy in pediatric heart transplant recipients. J Heart Lung Transplant 1999: 18: 460–469.
- 11 Ault BH, Honaker MR, Gaber AO, et al. Short-term outcomes of thymoglobulin induction in pediatric renal transplant recipients. Pediatr Nephrol 2002: 17: 815–818.
- 12 Parisi F, Danesi H, Squitieri C, Di Chiara L, Rava L, Di Donato RM. Thymoglobuline use in pediatric heart transplantation. J Heart Lung Transplant 2003: 22: 591–593.
- 13 Azeka E, Marcial MB, Jatene M, Auler JOC, Ramires JAF. Eight-year experience of pediatric heart transplantation: clinical outcome using non-invasive methods for the evaluation of acute rejection. Pediatr Transplant 2002: 6: 208–213.
- 14 Brophy PD, Thomas SE, McBryde KD, Bunchman TE. Comparison of polyclonal induction agents in pediatric renal transplantation. Pediatr Transplant 2001: 5: 174–178.
- 15 Garcia CD, Barros VR, Schneider L, Alves MD, Silveira CG, Garcia VD. IL-2 antibody induction and the outcome of pediatric renal transplants. Transplant Proc 2002: 34: 2914–2915.
- 16 Ciancio G, Burke GW, Suzard K, et al. Effects of daclizumab, tacrolimus and mycophenolate mofetil in pediatric first renal transplant recipients. Transplant Proc 2002: 34: 1944–1945.
- 17 Garcia CD, Schneider L, Barros VR, Guimaraes PC, Garcia VD. Pediatric renal transplantation under tacrolimus or ciclosporine immunosuppression and basiliximab induction. Transplant Proc 2002: 34: 2533–2534.
- 18 Vester U, Kranz B, Testa G, et al. Efficacy and tolerability of interleukine-2 receptor blockade with basiliximab in pediatric renal transplant recipients. Pediatr Transplant 2001: 5: 297–301.
- 19 Garcia Meseguer C, Vila Lopez A, Luque de Pablos A, Vallo Boado A, Simon JM, on behalf of the Pediatric EOSS Study Group. Immunoprophylaxis with Simulect (basiliximab) in pediatric kidney transplant recipients: results from the routine clinical practice at 5 kidney transplant units. Transplant Proc 2003: 35: 1697–1698.
- 20 Swiatecka-Urban A, Garcia C, Feuerstein D, et al. Basiliximab induction improves the outcome of renal transplants in children and adolescents. Pediatr Nephrol 2001: 16: 693–696.
- 21 Offner G, Broyer M, Niaudet P, et al. A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients. Transplantation 2002: 74: 961–966.
- 22 Nevins T, Ettenger R, Potter D, et al. Daclizumab (Zenapax) in pediatric renal allograft. Final data. AST 18th meeting Chicago, abstract 469. Transplantation 1999: 67: S124.
- 23 Benfield M, Tejani A, Ping-Leung H. Comparative Study of the Safety, Efficacy, and Practice Patterns of Monoclonal Antibodies in Pediatric Renal Transplantation (Abstract). Washington DC, USA: American Transplant Congress, 2002.
- 24 Ganschow R, Broering DC, Stuerenburg I, Rogiers X, Hellwege HH, Burdelski M. First experience with basiliximab in pediatric liver graft recipients. Pediatr Transplant 2001: 5: 353–358.
- 25 Heffron TG, Pillen T, Smallwood GA, Welch D, Oakley B, Romero R. Pediatric liver transplantation with daclizumab induction. Transplantation 2003: 75: 2040–2043.
- 26 Asensio M, Margarit C, Chavez R, Ortega J, Charco R, Iglesias J. Induction with basiliximab reduces acute rejection in pediatric liver transplant patients treated with tacrolimus and steroids. Transplant Proc 2002: 34: 1970–1971.
- 27 Healey PJ, Hansen K, Perkins JD. Daclizumab induction immunosuppression in pediatric liver transplantation. Abstract 56, 8th annual congress of the International Liver Transplantation Society, Chicago. Liver Transplant 2002: 6: C14.
- 28 Sweet SC, Dela Morena MT, Shapiro SD, Mendeloff EN, Huddleston CB. Interleukine-2 receptor blockade with daclizumab decreases the incidence of acute rejection in pediatric lung transplantation. Abstract 211, ISHLT 21th Congress 2001, Vancouver, Canada. J Heart Lung Transplant 2001: 20: 221.
- 29 Abou-Jaoude M, Ghantous I, Almawi WY. Comparison of daclizumab, an interleukin-2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation. Mol Immunol 2003: 39: 1083–1088.
- 30 Lebranchu Y, Bridoux F, Buchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving mycophenolate mofetil -containing triple therapy. Am J Transplant 2002: 2: 48–56.
- 31 Clark G, Walsh G, Deshpande P, Koffman G. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation. Nephrol Dial Transplant 2002: 17: 1304–1309.
- 32 Szczech LA, Berlin JA, Feldman HI. The effect of antilymphocyte induction therapy on renal allograft survival. Ann Intern Med 1998: 128: 817–826.
- 33 Ciancio G, Mattiazzi A, Roth D, Kupin W, Mille J, Burke GW. The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants. Clin Transplant 2003: 17: 428–432.
- 34 Meier-Kriesche HU, Kaza H, Palekar SS, et al. The effect of Daclizumab in a high-risk renal transplant population. Clin Transplant 2000: 14: 509–513.
- 35 Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003: 76: 1331–1339.
- 36 Reding R, Gras J, Sokal E, Otte JB, Davies HFS. Steroid-free liver transplantation in children. Lancet 2003: 362: 2068–2070.
- 37 Heffron TG, Smallwood GA, Pillen T, et al. Liver transplant induction trial of daclizumab to spare calcineurin inhibition. Transplant Proc 2002: 34: 1514–1515.
- 38 Arora N, McKiernan PJ, Beath SV, de Ville de Goyet J, Kelly DA. Concomitant basiliximab with low-dose calcineurin inhibitor in children post-liver transplantation. Pediatr Transplant 2002: 6: 214–218.
- 39 Newell KA, Alonso EM, Whitington PF, et al. Post-transplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996: 62: 370–375.
- 40 Gao SZ, Chaparro SV, Perlroth M, et al. Post-transplant lymphoproliferative disease in heart and heart-lung transplant recipients: a 30-year experience at Stanford University. J Heart Lung Transplant 2003: 22: 505–514.
- 41 Shapiro R, Nalesnik M, McCauley J, et al. Post-transplant lymphoproliferative disorders in adults and pediatric renal transplant recipients receiving tacrolimus-based immunosuppression. Transplantation 1999: 8: 1851–1854.
- 42 Acott PD, Lawen J, Lee S, Crocker JFS. Basiliximab vs. ATG/ALG induction in pediatric renal transplants: comparison of herpes virus profile and rejection rates. Transplant Proc 2001: 33: 3180–3183.
- 43 Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with post-transplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003: 76: 1289–1293.
- 44 Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE. North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Risk factors for post-transplant lymphoproliferative disorder in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001: 71: 1065–1068.
- 45 Venzke A, Ganschow R, Grabhorn E, Rogiers X, Burdelski M. Basiliximab monotherapy B-cell lymphoma after pediatric liver transplantation and anti-CD20 therapy. Pediatr Transplant 2003: 7: 404–407.
- 46 Yao FY, Saab S, Bass NM, et al. Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores. Hepatology 2004: 39: 230–238.
- 47 Nelson DR, Soldevila-Pico C, Reed A, et al. Anti-interleukine 2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transplant 2001: 7: 1064–1070.
- 48 Strehlau J, Pape L, Offner G, Nashan B, Ehrich JH. Interleukine-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. Lancet 2000: 356: 1327–1328.
- 49 Beniaminovitz A, Itescu S, Lietz K, Donovan M, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukine-2 receptor with a monoclonal antibody. N Engl J Med 2000: 342: 613–619.
- 50 Arnold AN, Wombolt DG, Whelan TV, et al. Mycophenolate mofetil, with cyclosporine and prednisone, reduces early rejection while allowing the use of less antilymphocytic agent induction and cyclosporine in renal recipients with delayed graft function. Clin Transplant 2000: 14: 421–426.
- 51 Jungraithmayr T, Staskewitz A, Kirste G, et al. Pediatric renal transplantation with mycophenolate mofetil-based immunosuppression without induction: results after three years. Transplantation 2003: 75: 454–461.
Citing Literature
